Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 2Somatostatinoma 1Prostatic Neoplasms 1Pituitary Neoplasms 1Lymphoma, Mantle-Cell 1Growth Hormone-Secreting Pituitary Adenoma 1Colonic Neoplasms 1Carcinoma, Neuroendocrine 1Carcinoma, Merkel Cell 1Carcinoma, Islet Cell 1

Interventions

Rituximab 9Cyclophosphamide 9ibrutinib 7fludarabine phosphate 7Peripheral Blood Stem Cell Transplantation 7Whole-Body Irradiation 4Radiotherapy 4Filgrastim 4Cytarabine 4Bendamustine Hydrochloride 4fludarabine 3Vincristine 3Prednisone 3Mycophenolic Acid 3Melphalan 3Lenalidomide 3Etoposide 3Doxorubicin 3Carmustine 3Tacrolimus 2Pentostatin 2Pentetic Acid 2Methotrexate 2Magnetic Resonance Spectroscopy 2Dexamethasone 2Cyclosporine 2Cord Blood Stem Cell Transplantation 2CT-P10 2Bortezomib 2venetoclax 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Lymphoma, Mantle-Cell × Complementary Therapies × Clear all
NCT00003502 2013-07-10

Antineoplaston Therapy in Treating Patients With Mantle Cell Lymphoma

National Cancer Institute (NCI)

Phase 2 Withdrawn
Lymphoid

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡